endoluminal solutions, Inc. completed its second fiscal year on August 31, 2026, and began its third fiscal year on September 1, 2026.
During our second fiscal year, we expanded our team and strengthened both our development capabilities and organizational foundation in preparation for future growth.
We regard our third fiscal year as an important period for establishing the business foundation required as a medical device manufacturer.
We will accelerate preparations for regulatory approval, establish our quality management system, and further strengthen our development and manufacturing capabilities toward commercialization.
We will continue to pursue our mission of realizing a society with zero deaths from gastric cancer through the development and real-world implementation of innovative medical devices.